Feasibility of Outpatient Closed Loop Control With the iLet Bionic Pancreas in Cystic Fibrosis Related Diabetes

NACompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 26, 2021

Primary Completion Date

June 29, 2022

Study Completion Date

June 29, 2022

Conditions
Cystic Fibrosis-related Diabetes
Interventions
DEVICE

Bionic Pancreas

Bionic pancreas system: The bionic pancreas is an autonomous, self-learning system that requires only the subject's weight for initialization, and then autonomously adapts insulin dosing to maintain glycemic control. The bionic pancreas uses continuous glucose monitoring as input to the controller. The bionic pancreas can be used in a bi-hormonal configuration, administering both insulin and glucagon as well as an insulin only setting.

OTHER

Usual Care

Subjects will remain on home insulin regimen (either insulin pump or injectable insulin). Subjects in usual care will wear a study CGM even if in typical care does not include CGM use.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Beta Bionics, Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT03258853 - Feasibility of Outpatient Closed Loop Control With the iLet Bionic Pancreas in Cystic Fibrosis Related Diabetes | Biotech Hunter | Biotech Hunter